Acute myeloid leukaemia

British Medical Bulletin

Volumn 52, Issue 4, 1996, Pages 764-777

  Stevens, Richard F ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; CYTOSINE; DAUNORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLYCOPROTEIN P; HYDROCORTISONE; METHOTREXATE; MONOCLONAL ANTIBODY; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOPROPHYLAXIS; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DRUG TRANSPORT; HUMAN; IMMUNOPHENOTYPING; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA REMISSION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0030459388     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011581     Document Type: Review

References (53)

1. Weinstein HJ. Congenital leukaemia and the neonatal myeloproliferative disorders associated with Down's syndrome. Clin Hematol 1978; 7: 147
2. Miller RW. Persons with exceptionally high risk of leukaemia. Cancer Res 1967; 27: 2420
3. Osada S, Horibe K. A case of infantile acute monocytic leukaemia caused by vertical transmission of the mother's leukaemic cells. Cancer 1990; 65: 1146
4. Groopman J, Ellman L. Acute promyelocytic leukaemia. Am J Hematol 1979; 7: 395
5. Grier HE, Gelber RD et al. Prognostic factors in childhood acute myelogenous leukaemia. J Clin Oncol 1987; 5: 1026
6. Fialkow PJ, Singer JW et al. Acute nonlymphocytic leukaemia: expression in cells restricted to granulocytic and monocytic differentiation. N Engl J Med 1979; 301: 1
7. Fearon ER, Burke PJ et al. Differentiation of leukaemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukaemia. N Engl J Med 1986; 315: 15
8. Smith LJ, Curtis JE et al. Lineage infidelity in acute leukaemia. Blood 1983; 61: 1138
9. Walker H, Smith FJ, Betts DR. Cytogenetics in acute myeloid leukaemia. Blood Rev 1994; 8: 30-6
10. Rowley JD. Identification of a translocation with quinacrine mustard fluorescence in a patient with acute leukaemia. Ann Genet 1973; 16: 109-12
11. Downing JR, Head DR, Curio-Brim AM. An AML/ETO fusion transcript is consistently detected by polymerase chain reaction in acute myelogenous leukaemia containing the t(8;21)(q22;q22) translocation. Blood 1993; 81: 2860-5
12. Larson RA, Kondo K, Vardiman J et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukaemia. Am J Med 1984; 76: 827-41
13. Dauwerse JG, Kievits T, Beverstock GC et al. Rapid detection of chromosome 16 inversion in acute nonlymphocytic leukaemia, subtype M4: regional localisation of breakpoint in 16p. Cytogenet Cell Genet 1990; 53: 126-8
14. Marie J-P. P-glycoprotein in adult hematological malignancies. Hematol Oncol Clin N Am 1995; 9: 239-49
15. Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137
16. Paietta J, Andersen J et al. Modulation of multidrug resistance in de novo adult acute myeloid leukaemia: variable efficacy of reverting agents in vitro. Blood Rev 1995; 9: 47-52
17. Gale RP. Advances in the treatment of acute myelogenous leukaemia. N Engl J Med 1979; 300: 1189-99
18. Lampkin BC, Woods W, Strauss R, et al. Current status of the biology and treatment of acute non-lymphocytic leukaemia in children. Blood 1983; 61: 215-28
19. Dahl GV, Kalwinsky DK, Murphy S et al. Cytokinetically based induction chemotherapy and splenectomy for childhood acute non-lymphocytic leukaemia. Blood 1982; 60: 856-63
20. Weinstein HJ, Mayer RJ, Rosenthal DS, et al. Treatment of acute myelogenous leukaemia in children and adults. N Engl J Med 1980; 303: 473-8
21. Creutzig U, Ritter J, Riehm H et al. Improved treatment results in childhood acute myelogenous leukaemia: a report of the German co-operative study AML-BFM-78. Blood 1985; 65: 298-304
22. Goldie JH, Coldman AJ. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439-49
23. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high dose cytosine arabinoside and asparaginase intensification on childhood acute myeloid leukaemia: a report from the Children's Cancer Group. J Clin Oncol 1993; 11: 538-45
24. Bloomfield CD. Post remission therapy in acute myeloid leukaemia. J Clin Oncol 1985; 3: 1570-2
25. Baehner RL, Kennedy A, Sather H et al. Characteristics of children with acute non-lymphoblastic leukaemia in long-term continuous remission: a report of the Children's Cancer Study Group. Med Pediatr Oncol 1981; 9: 393-403
26. Preisler H, Davis RB, Kirshner J et al. Comparison of three remission induction regimens and two post induction strategies for treatment of acute non lymphocytic leukaemia: a cancer and leukaemia group B study. Blood 1987; 69: 1441-9
27. Grier HE, Gelber RD, Link MP et al. Intensive sequential chemotherapy for children with acute myelogenous leukaemia: VAPA, 80-035, and HI-C-Daze. Leukaemia 1992; 6: 48-51
28. Steuber CP, Civin C, Krisher J et al. A comparison of induction and maintenance therapy for acute nonlymphocytic leukaemia in childhood: results of a Pediatric Oncology Group Study. J Clin Oncol 1991; 9: 247-58
29. Grier HE, Gelber RD, Camitta BM et al. Prognostic factors in childhood acute myelogenous leukaemia. J Clin Oncol 1987; 5: 1026-32
30. Kalwinsky D, Mirro J, Schell B et al. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukaemia: improved remission induction with a five drug regimen including etoposide. J Clin Oncol 1988; 6: 1134-43
31. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukaemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990; 75: 1932-40
32. Well RJ, Woods WG, Lampkin BC et al. Impact of high dose cytarabine and asparaginase intensification on childhood acute myeloid leukaemia: a report from the Children's Cancer Group. J Clin Oncol 1993; 11: 538-45
33. Woods WG, Ruymann FB, Lampkin BC et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukaemia. Cancer 1990; 66: 1106-13
34. Krischer JP, Steuber CP, Vietti TJ et al. Long term results in the treatment of acute nonlymphocytic leukaemia. Med Pediatr Oncol 1989; 17:401-8
35. Buckley JD, Chard RL, Baehner RL et al. Improvement in outcome for children with acute nonlymphocytic leukaemia. A report from the Children's Cancer Study Group. Cancer 1989; 63: 1457-65
36. Stevens RF, Hann IM, Wheatley K et al. Intensive chemotherapy with or without bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia. Leukaemia 1992; 6: 55-8
37. Pui C-H, Dahl GV, Kalwinsky DK et al. Central nervous system leukaemia in children with acute nonlymphoblastic leukaemia. Blood 1985; 66: 1062-7
38. Weinstein HJ, Mayer RJ, Rosenthal DS et al. Chemotherapy for acute myelogenous leukaemia in children and adults: VAPA update. Blood 1983; 62: 315-9
39. Dahl GV, Kalwinsky DK, Murphy S et al. Cytokinetically based induction chemotherapy and splenectomy for childhood acute lymphoblastic leukaemia. Blood 1982; 60: 856-63
40. Creutzig U, Ritter J, Zimmerman M et al. Does cranial irradiation reduce the risk of bone marrow relapse in acute myelogenous leukaemia? Unexpected results of the Acute Myelogenous Leukaemia Study BFM-87. J Clin Oncol 1993; 11: 279-86
41. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991; 7: 9-12
42. Hann IM, Stevens RF, Wheatley K et al. Marked improvements in outcome in paediatric acute myeloid leukaemia: preliminary results of the United Kingdom Medical Research Council's 10th AML Trial. J Clin Oncol 1996; In press
43. Dahl GV, Kalwinsky DK, Mirro J et al. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphoblastic leukaemia in first remission. J Clin Oncol 1990; 8: 295-303
44. Nesbit ME, Buckley JD, Feig SA et al. Chemotherapy for induction of remission of childhood acute myeloid leukaemia followed by marrow transplantation or multiagent chemotherapy: a report of the Children's Cancer Group. J Clin Oncol 1994; 12: 127-35
45. Feig SA, Lampkin B, Nesbit ME et al. Outcome of BMT during first complete remission of AML: a comparison or two sequential studies by the Children's Cancer Group. Bone Marrow Transplant 1993; 12: 127-35
46. Yeager AM, Kaizer H, Santos GW et al. Autologous bone marrow transplantation in patients with acute nonlymphoblastic leukaemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986; 315: 141-7
47. Ball ED, Mills LE, Coughlin CT et al. Autologous bone marrow transplantation in acute myelogenous leukaemia: in vitro treatment with myeloid specific monoclonal antibodies. Blood 1986; 68: 1311-5
48. Behar C, Bertrand Y, Rubie H. Mitoxantrone and high dose Ara-c for treatment of acute nonlymphoblastic leukaemia in childhood: a pilot study of the EORTC CLCG (EORTC 58-872). Leukaemia 1992; 6: 63-5
49. Amadori S, Testi AM, Moteli ML et al. Therapy of childhood acute myelogenous leukaemia (AML): the AIEOP LAM 87 and LAM 87 M studies. Med Pediatr Oncol 1992; 20: 387
50. Ravindranath Y, Yeager A, Krischer J et al. Intensive consolidation chemotherapy (ICC) vs purged autologous bone marrow transplantation (ABMT) early in remission for treatment of childhood acute myeloid leukaemia (AML): preliminary results of the Pediatric Oncology Group (POG) study 8821. Proc Am Soc Clin Oncol 1994; 13: 320
51. Wells R, Woods W, Buckley J et al. Five drug (5Dr) vs two drug (7+3) induction, bone marrow transplant (BMT) vs chemotherapy (C) and maintenance (M) vs no M (NM) in childhood acute myeloid leukaemia. Proc Am Soc Clin Oncol 1994; 13: 317
52. Lie SO, Gustafsson G, Jonmundsson G et al. A population based study of children with AML in the five Nordic countries. Treatment results and risk factors before and after intensification of the protocol. Med Pediatr Oncol 1992; 20: 386
53. Hahlen K, Berg A, Bokkerink J et al. Six months of intensive chemotherapy for childhood ANLL: results of the study ANLL-87 of the Dutch Childhood Leukaemia Study Group. Med Pediatr Oncol 1992; 20: 439